Most people who get their cholesterol checked never learn about lipoprotein(a). The particle does not appear on a standard lipid panel. Statins do not lower it. And until recently, even cardiologists debated how much it mattered. A pooled analysis of stored blood samples from more than 20,000 adults across three landmark NIH-funded trials now offers some of the clearest evidence yet: people with high Lp(a) levels faced a 31 percent greater rate of heart attack, stroke, or cardiovascular death over roughly four years, independent of every conventional risk factor clinicians already track.
The findings, drawn from participants in the ACCORD, PEACE, and SPRINT randomized controlled trials, land at a moment when late-stage clinical trials are testing drugs designed specifically to slash Lp(a) by 80 percent or more. If those drugs work, Lp(a) testing could shift from a specialist curiosity to a routine part of preventive care. If they do not, roughly one in five to one in six adults will remain stuck with an inherited cardiovascular risk factor and no targeted way to treat it.
What the pooled analysis found
Researchers measured Lp(a) in stored plasma from 20,070 participants enrolled in three federally funded trials. SPRINT, the largest contributor, included roughly 9,361 non-diabetic adults at elevated cardiovascular risk. ACCORD focused on patients with type 2 diabetes, and PEACE enrolled people with stable coronary artery disease and preserved heart function. Across all three studies, participants were followed for a median of approximately 3.98 years.
During that window, 1,461 participants (7.3 percent of the pooled cohort) experienced a major adverse cardiovascular event, defined as heart attack, stroke, or cardiovascular death. Among those whose Lp(a) measured at or above 175 nmol/L, the adjusted hazard ratio for that composite endpoint was 1.31 compared with participants at lower levels. Cardiovascular death on its own also carried an elevated hazard ratio in the high-Lp(a) group. Crucially, these associations held after adjustment for age, sex, blood pressure, LDL cholesterol, diabetes status, and statin use, reinforcing the idea that Lp(a) represents a distinct layer of risk that standard treatments leave unaddressed.
A separate individual-patient meta-analysis of statin outcome trials, published in The Lancet in 2018, confirmed a related point: statins do not materially reduce Lp(a). That analysis, led by researchers including Peter Willeit and colleagues, showed that higher baseline and on-statin Lp(a) levels predicted cardiovascular events, including stroke, regardless of whether patients were taking statins. In practical terms, a patient can hit textbook LDL targets and still carry substantial residual risk if their Lp(a) is genetically elevated.
Why Lp(a) is different from ordinary cholesterol
The reason Lp(a) has been so difficult to address is biological. Unlike LDL cholesterol, which responds to diet, exercise, and a range of medications, Lp(a) concentrations are roughly 80 to 90 percent determined by genetics, according to decades of twin and family studies. Levels are largely set at birth and remain stable across a person’s lifetime. A 25-year-old with high Lp(a) will almost certainly still have high Lp(a) at 65, regardless of how they eat or how many miles they run.
That stability is why most experts say the test needs to be done only once in adulthood. But standard lipid panels ordered during routine checkups do not include Lp(a) unless a clinician specifically requests it, which means many people with elevated levels have never been identified. The test itself is a simple blood draw, typically costing between $20 and $50 when ordered through a lab, though insurance coverage varies.
Prevalence also varies by ancestry. Research has consistently shown that Black adults tend to have higher median Lp(a) levels than white adults, a disparity driven by genetic variation in the LPA gene rather than by lifestyle factors. This raises equity concerns: a risk factor that disproportionately affects certain populations is also one that most of those populations have never been tested for.
What remains uncertain
Several gaps limit how far these findings can be extended. The pooled dataset relied on stored plasma rather than prospectively collected Lp(a) measurements, and the original trials were not designed to test Lp(a) as a primary exposure. Participant-level demographic breakdowns linking Lp(a) to outcomes by age, race, or baseline kidney function in the ACCORD, PEACE, and SPRINT subsets have not been fully reported in primary sources.
An open question is whether elevated Lp(a) modifies the benefit of intensive blood-pressure control observed in SPRINT. The original trial showed that targeting a systolic pressure below 120 mmHg reduced cardiovascular events compared with the standard target of below 140 mmHg. If high Lp(a) blunts or amplifies that benefit, it could change how clinicians weigh aggressive blood-pressure treatment in patients who also carry genetic lipid risk. As of June 2026, no published subgroup analysis has tested this interaction.
The biggest clinical unknown is whether lowering Lp(a) with drugs actually prevents heart attacks and strokes. Observational data and Mendelian randomization studies, which use naturally occurring genetic variation as a proxy for lifelong exposure, strongly suggest it should. People born with genetically lower Lp(a) have fewer cardiovascular events. But no completed randomized trial has yet proven that pharmacologically reducing Lp(a) translates into fewer events.
Drugs in the pipeline
Several programs are now testing that hypothesis directly. A phase III trial (NCT05537571) is evaluating zerlasiran, a small interfering RNA (siRNA) therapy developed by Silence Therapeutics in partnership with Novo Nordisk, in participants with elevated Lp(a) who are at high risk of atherosclerotic cardiovascular disease events. Separately, Novartis is running the HORIZON trial (NCT05581303) for pelacarsen, an antisense oligonucleotide that targets Lp(a) production in the liver. Both drugs have demonstrated the ability to cut Lp(a) levels by 80 percent or more in earlier-phase studies.
Results from these trials could begin arriving within the next one to two years. If they show a meaningful reduction in heart attacks, strokes, and cardiovascular deaths, Lp(a) testing is likely to move from a niche consideration to a standard component of cardiovascular risk assessment, and new treatment guidelines will follow quickly.
What patients and clinicians can do now
Until those outcome trials report, management focuses on reducing overall cardiovascular risk rather than Lp(a) itself. For individuals found to have high Lp(a), clinicians typically emphasize aggressive control of every modifiable factor: lowering LDL cholesterol with statins and, if needed, additional agents such as ezetimibe or PCSK9 inhibitors; treating high blood pressure and diabetes; encouraging smoking cessation; and reinforcing diet and exercise changes. The logic is straightforward: if one major risk factor cannot yet be treated directly, tightening every other lever becomes more important, not less.
Some existing therapies do reduce Lp(a) to a degree. PCSK9 inhibitors such as evolocumab and alirocumab lower Lp(a) by roughly 25 to 30 percent, based on subanalyses from the FOURIER and ODYSSEY OUTCOMES trials. Lipoprotein apheresis, a procedure that physically filters lipoproteins from the blood, can produce larger reductions but requires regular sessions and is available only at specialized centers. Neither therapy is currently prescribed primarily for Lp(a) lowering in most clinical settings, constrained by cost, coverage decisions, and limited evidence that Lp(a)-specific reduction improves outcomes.
Guideline bodies have begun to acknowledge Lp(a) as a risk-enhancing factor. The European Atherosclerosis Society recommends measuring Lp(a) at least once in every adult’s lifetime. The American Heart Association and American College of Cardiology list elevated Lp(a) as a risk-enhancing factor that can tip borderline patients toward statin therapy, but stop short of endorsing universal screening. The gap between European and American recommendations reflects an ongoing debate: is it useful to identify a risk factor you cannot yet target with a specific drug?
Why this study changes the conversation
What the pooled analysis adds is scale and rigor in a field that has long relied on smaller observational cohorts. Drawing on three well-conducted, federally funded randomized trials gives the dataset a level of internal validity that single-center studies cannot match. Combined with the Lancet meta-analysis showing that statins leave Lp(a)-driven risk untouched, the evidence now forms two independent lines pointing in the same direction: Lp(a) is common, measurable, genetically fixed, and associated with serious cardiovascular outcomes that current first-line therapies do not fully address.
For the estimated 15 to 20 percent of adults walking around with elevated Lp(a) and no idea, the practical first step is simple. Ask for the test. A single blood draw can reveal whether this inherited risk factor is part of the picture. It will not unlock a targeted drug today, but it can prompt earlier, more intensive use of the tools that already work and ensure that a hidden genetic factor is not quietly shaping outcomes no one thought to look for.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
